Benzoyl peroxide/clindamycin low dose - Valeant Pharmaceuticals

Drug Profile

Benzoyl peroxide/clindamycin low dose - Valeant Pharmaceuticals

Alternative Names: Acanya Gel; BenzaClin Topical Gel; Clin-BPO 2.5%; Clindamycin phosphate 1.2% and benzoyl peroxide 2.5%; Clindamycin phosphate 1.2% and benzoyl peroxide 3.75%; Clindamycin/benzoyl peroxide - Valeant Pharmaceuticals; IDP-110; ONEXTON Gel

Latest Information Update: 28 Sep 2015

Price : $50

At a glance

  • Originator Arcutis Pharmaceuticals
  • Developer Valeant Pharmaceuticals International
  • Class Antiacnes; Antibacterials; Benzoic acids; Lincosamides; Oxidants; Small molecules
  • Mechanism of Action Keratinocyte inhibitors; Protein 50S ribosomal subunit inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne vulgaris

Most Recent Events

  • 22 Sep 2015 Generic equivalent available in USA for Acne vulgaris
  • 25 Nov 2014 The US FDA approves benzoyl peroxide/clindamycin gel 3.75%/1.2% for Acne vulgaris
  • 25 Nov 2014 Efficacy and adverse events data from a pivotal trial in Acne vulgaris released by Valeant Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top